CCL2 and familial pancreatic carcinoma: Similarly, type I angiotensin II receptors were reported to regulate CCL2 in prostate cancer and pancreatic cancer cells, suggesting that losartan, and potentially other type I angiotensin II receptor blockers, could be repurposed for use in cancer immunotherapy [106,107].